Program
Gabapentin
Also written as “gabapentin”, “gabapentin 600 mg” and “Gabapentin Extended Release tablets”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Hot Flashes · Diabetic Neuropathies · Epilepsies, Partial · Neuralgia, Postherpetic, led by 8 companies.
Drug pageGabapentin: every studyMany companies study it; this page follows only the 44 they lead. All 334 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatris | 201 open or running | phase 4since Sep 28, 2007 | Sep 8, 2005 | Jan 31, 2027phase 4 · NCT07813026 |
| Depomedits history only | 80 open or running | phase 4since Jun 5, 2017 | Jun 8, 2006 | none ahead |
| Teva Pharmaceutical Industriesits history only | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 40 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Sep 29, 2011 | Sep 29, 2011 | none ahead |
| Pharmaceutical Research Management srlits history only | 20 open or running | phase 3since Mar 18, 2016 | Mar 18, 2016 | none ahead |
| Nang Kuang Pharmaceuticalits history only | 10 open or running | phase 4since Feb 24, 2014 | Feb 24, 2014 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since May 5, 2010 | May 5, 2010 | none ahead |
Also a collaborator on its studies: Chiltern International and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Sep 8, 2005.
- Dec 21, 2007Phase 4 study in Renal InsufficiencyNCT00584779 · 8 enrolled · Japan
- Jan 16, 2008Phase 3 study in Epilepsies, PartialNCT00603473 · 92 enrolled · Japan
- Feb 11, 2008Phase 3 study in Epilepsies, PartialNCT00620555 · 65 enrolled · Japan
- Mar 25, 2008Phase 4 study in Diabetic NeuropathiesNCT00644748 · 95 enrolled · Brazil
- Apr 1, 20085 phase 3 studies in Sleep Initiation and Maintenance DisordersNCT00659100, NCT00667108, NCT00666939 and 2 more
- Apr 23, 2008Phase 4 study in Sleep Initiation and Maintenance DisordersNCT00666796 · 20 enrolled · United States
- May 6, 2008Phase 3 study in Sleep Initiation and Maintenance DisordersNCT00674752 · 377 enrolled · United States
- Nov 3, 2008Phase 4 study in Renal InsufficiencyNCT00785772 · 1 enrolled · Japan
- Sep 30, 2009Phase 1 study in HealthyNCT00987779 · 26 enrolled · Singapore
- Jun 25, 2013Phase 3 study in Sleep Initiation and Maintenance DisordersNCT01888497 · 59 enrolled · United States
- Sep 24, 2020Phase 4 study in Abuse PotentialNCT04570436 · 52 enrolled · United States
- Mar 8, 2022Phase 4 study in Abuse PotentialNCT05319756 · 54 enrolled · United States
- Aug 17, 2026Phase 4 study in Healthy Non-dependent, Recreational Sedative UsersNCT07777965 · 44 enrolled · United States
- Sep 4, 2026Phase 4 study in HealthyNCT07813026 · 60 planned · United States
Ahead
- Jan 31, 2027Primary completion: phase 4 study in HealthyNCT07813026
TargetBeta
“Voltage-gated calcium channel modulator”ChEMBL 37, by rule
Other programs on the same 26 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pregabalinrule | Viatris | phase 4 | 149 |
Studies
All 20 Viatris leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07813026Healthy · United States | 4 | Recruiting | Jan 31, 2027 | 60 |
| NCT07777965Healthy Non-dependent, Recreational Sedative Users · United States | 4 | Completed | Aug 31, 2026 | 44 |
| NCT05319756Abuse Potential · United States | 4 | Completed | Dec 31, 2021 | 54 |
| NCT04570436Abuse Potential · United States | 4 | Completed | Nov 10, 2022 | 52 |
| NCT01888497Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | Dec 14, 2013 | 59 |
| NCT00987779Healthy · Singapore | 1 | Completed | Oct 2009 | 26 |
| NCT00785772Renal Insufficiency · Japan | 4 | Terminated | Apr 2010 | 1 |
| NCT00674752Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 377 | |
| NCT00667108Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 784 | |
| NCT00666939Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 773 | |
| NCT00666796Sleep Initiation and Maintenance Disorders · United States | 4 | Completed | 20 | |
| NCT00666770Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 309 | |
| NCT00666575Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 2,105 | |
| NCT00659100Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 1,254 | |
| NCT00644748Diabetic Neuropathies · Brazil | 4 | Completed | 95 | |
| NCT00620555Epilepsies, Partial · Japan | 3 | Completed | Dec 2010 | 65 |
| NCT00603473Epilepsies, Partial · Japan | 3 | Completed | Dec 2009 | 92 |
| NCT00584779Renal Insufficiency · Japan | 4 | Terminated | Dec 2007 | 8 |
| NCT00537940Epilepsy · Costa Rica, El Salvador, Guatemala and more | 4 | Completed | Jul 2013 | 482 |
| NCT00163046Sleep Initiation and Maintenance Disorders · United States | 3 | Completed | 256 |
How it is read
Names in the registry
- “Gabapentin”, 27 entries
- “gabapentin”, 5 entries
- “gabapentin 600 mg”, 3 entries
- “Gabapentin Extended Release tablets”, 3 entries
- “Gabapentin 800 mg tablets, single dose (1 tablet)”, 3 entries
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 10 studies
- Hot Flashes, 4 studies
- Diabetic Neuropathies, 3 studies
- Epilepsies, Partial, 3 studies
- Neuralgia, Postherpetic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.